[Molecular pathogenesis and therapeutic targets of lysosomal diseases].
Tsuji
Daisuke
D
Department of Medicinal Biotechnology, Institute of Health Biosciences, The University of Tokushima, 1-78 Sho-machi, Tokushima 770-8505, Japan.
Itoh
Kohji
K
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004195:Disease Models, Animal; D049289:G(M2) Activator Protein / Q000235:genetics; D015316:Genetic Therapy; D006801:Humans; D020140:Lysosomal Storage Diseases, Nervous System / Q000235:genetics* / Q000628:therapy*; D009154:Mutation; D001619:beta-N-Acetylhexosaminidases / Q000235:genetics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D049289:G(M2) Activator Protein; D017485:1-Deoxynojirimycin; C059896:miglustat; D001619:beta-N-Acetylhexosaminidases; D001241:Aspirin